Biognosys has presented its extended plasma proteomics services for deep and high throughput in biomarker discovery. According to a statement, the combinations of depth and throughput can be regulated for different research needs.
Using an innovative plasma enrichment method, the Biognosys TrueDiscovery platform now reportedly enables a depth of up to 7000 protein groups in plasma or serum. The new version also includes a high-throughput workflow with a depth of up to 4500 protein groups. The seamless transition from discovery to targeted proteomics allows rapid validation of biomarker candidates, writes the company.
Biognosys combines this innovative method with “highly optimized DIA workflows and machine learning-augmented data analysis in Spectronaut”, according to Dr. Roland Bruderer from Biognosys. Therefore, “we once again push the boundaries of depth and throughput that can be achieved with our TrueDiscovery platform in plasma,” he said. Spectronaut is a software developed by Biognosys.
The combinations of depth and throughput that mass spectrometry proteomics can now achieve “were completely out of reach until recently”, Biognosys CEO and Co-Founder Oliver Rinner, is quoted as saying. “I am thrilled about the impressive performance gains we are seeing with plasma enrichment and the further innovation potential this method still holds for making the plasma proteome truly actionable in large-scale, clinical studies.”
Biognosys is a spinoff from the Federal Institute of Technology in Zurich. It is headquartered in the Bio-Technopark Schlieren-Zürich. ce/mm
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com